AHK-Cu (Alanine-Histidine-Lysine Copper) vs Klotho
A neutral, side-by-side comparison of two anti-aging & longevity peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
AHK-Cu (Alanine-Histidine-Lysine Copper)
Copper-chelating tripeptide structurally related to GHK-Cu but optimized for scalp and hair follicle applications. AHK-Cu activates hair follicle stem cells and prolongs the anagen (active growth) phase, making it a key research compound for androgenetic alopecia and diffuse hair loss. Used topically as an alternative or complement to minoxidil and finasteride.
Full profileKlotho
Anti-aging protein discovered in 1997 whose deficiency causes a syndrome resembling accelerated aging across multiple organ systems. Circulating soluble klotho declines ~40% from age 40–80. Research into klotho-derived peptides and recombinant protein explores neuroprotection, cardiac protection, renal anti-fibrosis, and metabolic anti-aging benefits. The KL-VS polymorphism provides a natural human model of elevated klotho activity.
Full profile| AHK-Cu (Alanine-Histidine-Lysine Copper) | Klotho | |
|---|---|---|
| Category | Anti-Aging & Longevity | Anti-Aging & Longevity |
| Also known as | AHK copper peptide, Ala-His-Lys copper, hair growth copper peptide, AHK-copper complex | α-Klotho, soluble Klotho, KL-VS, klotho protein, KL1 domain |
| Evidence | Research-stage | Research-stage |
| Dosing range | 0.1%–1% %, Daily topical application (scalp) | 1mcg/kg–10mcg/kg mcg/kg, every 3–7 days IV or SC (research) |
| Administration | Topical (scalp serum/solution), Subcutaneous (microneedling-assisted delivery) | Intravenous (research), Subcutaneous injection |
| Key side effects | Mild scalp irritation, Contact dermatitis (rare), Temporary scalp redness or tingling, Transient scalp shedding at initiation (shedding phase) | Hypophosphatemia (klotho inhibits FGF23 signaling → phosphate wasting), Hypocalcemia (secondary to phosphate effects), Altered vitamin D metabolism, Potential for altered mineral homeostasis with chronic administration |
| Cited sources | 2 references | 2 references |
Key differences
- Administration: AHK-Cu (Alanine-Histidine-Lysine Copper) — Topical (scalp serum/solution), Subcutaneous (microneedling-assisted delivery); Klotho — Intravenous (research), Subcutaneous injection.
- Dosing units differ: AHK-Cu (Alanine-Histidine-Lysine Copper) is dosed in %, Klotho in mcg/kg — they operate at different scales.
- Frequency: AHK-Cu (Alanine-Histidine-Lysine Copper) is typically Daily topical application (scalp); Klotho is every 3–7 days IV or SC (research).
How each works
AHK-Cu (Alanine-Histidine-Lysine Copper)
AHK-Cu activates β-catenin/Wnt signaling in dermal papilla cells and promotes VEGF expression around hair follicles. Studies demonstrate extended anagen phase duration, increased follicle size, and upregulation of hair growth factors in treated scalp tissue. The copper component supports tyrosinase activity for follicle pigmentation and metalloenzymes involved in extracellular matrix remodeling around follicles.
Klotho
α-Klotho functions as both a transmembrane co-receptor for FGF23 (regulating phosphate and vitamin D) and as a shed soluble circulating factor with FGF23-independent longevity effects. Soluble klotho activates longevity-associated pathways: Nrf2/antioxidant defense, FOXO transcription factors, and Wnt/TGF-β inhibition for anti-fibrotic effects. The klotho-deficient mouse ages rapidly and dies young; klotho-overexpressing mice live 20–30% longer.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.